Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Operating Leases: 2019-2025

Historic Operating Leases for Cidara Therapeutics (CDTX) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • Cidara Therapeutics' Operating Leases fell 39.99% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 39.99%. This contributed to the annual value of $1.6 million for FY2024, which is 45.90% down from last year.
  • Per Cidara Therapeutics' latest filing, its Operating Leases stood at $2.0 million for Q3 2025, which was down 14.96% from $2.3 million recorded in Q2 2025.
  • Cidara Therapeutics' Operating Leases' 5-year high stood at $3.9 million during Q1 2024, with a 5-year trough of $315,000 in Q3 2022.
  • In the last 3 years, Cidara Therapeutics' Operating Leases had a median value of $3.2 million in 2023 and averaged $2.9 million.
  • In the last 5 years, Cidara Therapeutics' Operating Leases slumped by 88.11% in 2022 and then surged by 949.52% in 2023.
  • Over the past 5 years, Cidara Therapeutics' Operating Leases (Quarterly) stood at $1.3 million in 2021, then plummeted by 88.11% to $315,000 in 2022, then skyrocketed by 949.52% to $3.0 million in 2023, then tumbled by 45.90% to $1.6 million in 2024, then slumped by 39.99% to $2.0 million in 2025.
  • Its Operating Leases was $2.0 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.7 million in Q1 2025.